At RoukenBio, we are an immunotherapy CRO offering tailored, human-relevant immunotherapy solutions to meet the specific needs of your unique therapeutic programmes. We design and run immunotherapy assays using engineered cell lines and primary human immune cells to help you understand mechanism of action, differentiate candidates, and identify early safety signals fast, collaboratively, and with uncompromising data quality.
Whether you’re developing antibodies, multispecifics, ADCs, cytokine-fusions, or cell therapies, we build the right in vitro models around your biology so you can progress with confidence in your immunotherapy drug development journey.
Our broad experience across therapeutic fields makes us the premier partner for developing innovative therapies. Our philosophy is to comprehensively understand a therapeutic’s mechanisms of action by creating in vitro models that closely mimic disease biology, generating meaningful data for informed decision-making and early identification of potential safety concerns.
Immuno-oncology is redefining cancer treatment by mobilising the immune system to recognise and eliminate tumour cells. Yet, resistance, immune evasion, and toxicity remain key challenges. Our immune cell assays are built to model immune–tumour interactions in vitro, helping you evaluate potency, immune activation, tumour killing, and functional biology in physiologically relevant systems.
Autoimmune and inflammatory diseases arise from immune dysregulation, leading to chronic tissue damage and complex, patient-specific biology. We deliver immunotherapy services that translate disease-relevant immunology into actionable assays, supporting target validation, lead selection, and characterisation of mechanisms that modulate immune pathways without relying on broad immunosuppression.
Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.
As an immunology CRO, we specialise in immunology-led therapeutic areas including immuno-oncology, autoimmunity, inflammation and allergy, and we routinely adapt our approaches to adjacent immune-mediated indications as programmes evolve.
Allergic disease spans mild symptoms through severe systemic reactions and is driven by coordinated innate and adaptive immune mechanisms. We provide immunotherapy assays using relevant effector and helper cell biology to help you interrogate mechanism, functional impact, and safety, supporting the development of next-generation therapies designed for precision immune modulation.
